What question did this study set out to answer?

This study aims to evaluate the correlation between PD-L1 expression in cancer associated macrophage-like cells and clinical outcomes in metastatic breast cancer patients receiving immunotherapy.

February 22, 2026Clinical Cancer Research

Abstract PS2-09-25: Monitoring Upregulation of PD-L1 in Cancer Associated Macrophage-Like Cells in Blood Predicts Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

View Full Paper

Ask AI

Bookmark

Authors

DAD. L. AdamsCreatv MicroTech (United States)MCM. CristofanilliCornell University CRC. ReduzziCornell University

Discussion

Member takes

Implication

Pilot study shows monitoring PD-L1 in blood correlates with clinical outcomes in metastatic breast cancer patients undergoing immunotherapy, indicating potential for patient stratification.

Key Points

This study aims to evaluate the correlation between PD-L1 expression in cancer associated macrophage-like cells and clinical outcomes in metastatic breast cancer patients receiving immunotherapy.
Conducted a prospective pilot study with 67 metastatic breast cancer patients on systemic therapy and immunotherapy.
Isolated cancer associated macrophage-like cells (CAML) from blood samples and measured PD-L1 expression before and after treatment.
Analyzed progression-free survival (PFS) and overall survival (OS) using univariate analysis over two years.
44% of patients had high PD-L1 expression in CAMLs at baseline, but it did not correlate with PFS or OS.
58% had high PD-L1 at follow-up, correlating with significantly improved PFS and OS.
Patients with consistently low PD-L1 had the poorest outcomes, while those with high PD-L1 at both time points had the best responses.

Cite This Study

Adams et al. (2026) studied this question.

synapsesocial.com/papers/699a9dcd482488d673cd3f2b https://doi.org/10.1158/1557-3265.sabcs25-ps2-09-25

View Full Paper

Ask AI

Bookmark

Implication

Pilot study shows monitoring PD-L1 in blood correlates with clinical outcomes in metastatic breast cancer patients undergoing immunotherapy, indicating potential for patient stratification.

Abstract PS2-09-25: Monitoring Upregulation of PD-L1 in Cancer Associated Macrophage-Like Cells in Blood Predicts Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS2-09-25: Monitoring Upregulation of PD-L1 in Cancer Associated Macrophage-Like Cells in Blood Predicts Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider